Medical device company Polartechnics (ASX:PLT) today announced it had secured commitments to raise $5 million to assist in international marketing of its three core products.

Sydney's Australian Technology Park biotech hub has grown to nine companies with two new businesses recently joining the BioFirst precinct.

Australian researchers have discovered two genes that are critical to understanding elite athletic performance, an Athens conference has heard.

Sydney-based Brain Resource Company (ASX:BRC) has cracked into the biotechnology sector with a deal to provide its profiles of brain function and cognition to Biogen in the United States.

Brisbane's Progen Industries (ASX:PGL) will take on production of an anti-cancer therapeutic vaccine for Prima Biomed's (ASX:PRR) Cancer Vac subsidiary.

Diagnostics group Visiomed (ASX:VSG) has entered a German research collaboration to develop surgical navigation systems for spinal procedures.

Circadian Technologies (ASX:CIR) has added another string to its neuroscience bow with an investment in new Melbourne research.

Norwood Abbey (ASX:NAL) is on track to list its immunology spin-off in the United Kingdom within six months.

Biota Holdings' (ASX:BTA) second-generation influenza program has leap-frogged into clinical trials thanks to a partnership with a Japanese competitor.

Biomedical nanotechnology company pSivida (ASX:PSD) will strengthen its stake in its United Kingdom operating subsidiary following a AUD$6.5 million capital raising, the biotech announced today.

Optiscan Imaging's (ASX: OIL) partnership with Japan's Pentax Corporation to develop a flexible endomicroscope has taken another step forward with the Melbourne biotech receiving its first major order for the supply of components.